

# CytoSorb® Best Practice



## Flowchart rhabdomyolysis



### Patient selection

- Confirmed/ suspected rhabdomyolysis with impending/existing acute kidney injury (AKI)
- Myoglobin levels  $> 10,000 \mu\text{g/l}$
- If myoglobin levels are unavailable, CK levels or myoglobinuria might provide clues as to the status or progression of the clinical condition (no direct removal of CK by the adsorber!)
- Contraindication for intensified fluid therapy



### Timing

- Ideally start within the first 24 hrs. after diagnosis/onset of severe rhabdomyolysis
- In general start early before irreversible damage occurs



### Dosing

- Consider changing adsorber after 8 hours until sufficient stabilization/clinical improvement has occurred or myoglobin levels well below  $5000 \mu\text{g/l}$  have been reached.



### START

Confirmed / suspected  
rhabdomyolysis with  
impending / existing  
acute kidney injury  
(AKI)

**Myoglobin  
> 10,000 µg/l \***

Additional potential criteria  
to decide on CytoSorb® use  
- Concomitant hyperinflammation  
- Refractory vasoplegic shock

NO

**Integrate CytoSorb®**

- ▶ Hemoperfusion
- ▶ CRRT
- ▶ ECMO

**Re-evaluation  
at regular intervals**

**Standard therapy  
continuation**

**BEGIN  
CytoSorb®**

**8 hrs. \*\***

**2nd  
Adsorber**

**8 hrs. \*\***

**3rd  
Adsorber**

**8 hrs. \*\***

**New  
Adsorber**

**12-24 hrs. \*\***

NO

**Sustained reduction  
in myoglobin with levels  
<< 5,000 µg/l \***

Additional potential criteria  
to decide on CytoSorb®  
- AKI improvement / recovery  
- Shock reversal

**YES**

**STOP  
CytoSorb®**

\* If myoglobin values are unavailable, CK levels or myoglobinuria may provide clues as to the status or progression in the clinical condition, but it should be noted that there is no direct removal of CK by the adsorber.

\*\* Depending on the individual's clinical course (e.g. persistent pronounced reduction in myoglobin levels) it may be possible to deviate from the indicated times to longer intervals, or even to terminate the therapy earlier. Sufficient control of the underlying cause is a prerequisite of therapeutic success.



Learn more in detail  
[cyto.zone/setup](https://cyto.zone/setup)

follow us on | [www.cytosorb.com](https://www.cytosorb.com)